TRIAGE-GS study looks at genome sequencing before genetics visits
A ClinicalTrials.gov registry observation shows TRIAGE-GS as active but not recruiting, testing whether genome sequencing before a geneticist visit can change diagnosis timing, utility, and costs in rare disease care.
A new registry observation shows TRIAGE-GS as ACTIVE_NOT_RECRUITING, with The Hospital for Sick Children listed as sponsor and primary completion estimated for 2028-03. For a general reader, the key point is simple: this study is testing whether genome sequencing can move earlier in the genetics workup for rare disease, instead of coming later after a geneticist visit.
The study is randomized and compares a GS-first arm with a Standard-of-care arm. In the GS-first arm, the intervention is listed as genome sequencing pre-geneticist evaluation, which makes the trial especially relevant to anyone following how hospitals try to shorten the path from symptoms to a diagnosis or a decision to stop active follow-up.
Its main outcome is a time-to-event measure: diagnosis or no active follow-up, tracked from randomization until disclosure of the diagnosis or plan, up to 18 months. The record says the composite event was chosen with input from patients, families, and clinicians, including cases where a negative genome sequencing result may reduce the need for more testing or short-term follow-up.
What the study is trying to measure
The registry entry also sets out two practical questions for care teams. One is clinical utility, measured with the C-GUIDE total score, and the other is personal utility, measured with the GENE-U total score. Both compare the GS-first approach with the first genetic test initiated by the geneticist in standard care.
A third piece is money. The study plans an incremental cost-effectiveness analysis, looking at the incremental cost per additional case detected from a healthcare system payer perspective, and also from the perspective of society. That makes the project about more than speed alone; it is also asking whether earlier sequencing is worth the resources it uses.
Why this fits the wider gene and cell therapy picture
This registry observation also sits inside the live Gene & Cell Therapy special event. Related studies in that collection span CAR T-cell therapy, stem cell transplantation, gene therapy, and other genetics-linked research, showing how broad the field is right now.
TRIAGE-GS is different from many of those treatment studies because it focuses on the front end of care: finding a diagnosis, deciding on next steps, and understanding when follow-up is no longer needed. That makes it a useful companion to the more intervention-heavy studies in the same topic area.
There are no posted results here, so this should be read as an active study in progress, not a concluded finding. For readers watching how genetics services evolve, the important takeaway is that TRIAGE-GS is trying to test whether earlier genome sequencing can make rare-disease care more efficient without losing clinical value.